NCT00877643|CompletedDMC
Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure
RACE 3
Loading search results
RACE 3
Sponsor study identifier
Secondary identifiers
interventional
250
2 countries
20
Study Start
May 4, 2009
Actual (reported)Primary Completion
February 1, 2018
Actual (reported)Study Completion
January 31, 2021
Actual (reported)The purpose of this study is to investigate whether in patients with early persistent atrial fibrillation and mild to moderate early heart failure an aggressive upstream rhythm control approach, including aldosterone receptor antagonists and statins, dietary restrictions, counseling and cardiac rehabilitation programs, increases persistence of sinus rhythm compared with conventional rhythm control after one year of follow-up. A randomized long term extension of the RACE 3 will be performed with a total follow-up of 5 years to investigate the long term effects on persistence of sinus rhythm and cardiovascular morbidity and mortality of the two treatment strategies.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 31, 2021
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 7, 2009
Actual (reported)April 8, 2009
Actual (reported)May 4, 2009
Actual (reported)February 1, 2018
Actual (reported)January 31, 2021
Actual (reported)Success of rhythm control strategy consisting of 1) the patient is still in a rhythm control strategy according to the attending physician, and 2) that sinus rhythm is maintained after 1 year of follow-up.
1 year after electrical cardioversion
Exploratory randomized long term extension of the RACE 3 study performed to study the long term effects of the two treatment strategies.
5 years after electrical cardioversion
Aldosterone receptor antagonists and statins, dietary restrictions, counseling, and cardiac rehabilitation.
Usual care for atrial fibrillation and heart failure according to the present guidelines
Ziekenhuisgroep Twente
Almelo, Netherlands
Onze Lieve Vrouwe Gasthuis
Amsterdam, Netherlands
Hospital Rijnstate
Arnhem, Netherlands
Ter Gooi Hospital
Blaricum, Netherlands
Amhia Hospital
Breda, Netherlands
Ommelander Hospital Group
Delfzijl, Netherlands
Deventer Hospital
Deventer, Netherlands
Nguyen BO, Crijns HJGM, Tijssen JGP, Geelhoed B, Hobbelt AH, Hemels MEW, Mol WJM, Weijs B, Alings M, Smit MD, Tieleman RG, Tukkie R, Van Veldhuisen DJ, Van Gelder IC, Rienstra M; RACE 3 Investigators. Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial. Europace. 2022 Jul 15;24(6):910-920. doi: 10.1093/europace/euab270.
Nguyen BO, Rienstra M, Hobbelt AH, Tijssen JGP, Smit MD, Tieleman RG, Geelhoed B, Van Veldhuisen DJ, Crijns HJGM, Van Gelder IC; RACE 3 Investigators. Optimal treatment of underlying conditions improves rhythm control outcome in atrial fibrillation - Data from RACE 3. Am Heart J. 2020 Aug;226:235-239. doi: 10.1016/j.ahj.2019.12.005. Epub 2020 Feb 14. No abstract available.
Marco Alings, MD, PhD
Amphia Hospital Breda
Isabelle C Van Gelder, MD, PhD
University Medical Center Groningen
Harry J Crijns, MD, PhD
Maastricht University Medical Center
250 participants (actual enrollment reported by the registry).
First Submitted
April 7, 2009
First Posted
April 8, 2009
Study Start
May 4, 2009
Actual (reported)Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Oosterscheldeziekenhuis
Goes, Netherlands
Martini Hospital
Groningen, Netherlands
University Medical Center Groningen
Groningen, Netherlands
Kennemer Gasthuis
Haarlem, Netherlands
Medical University Center Maastricht
Maastricht, Netherlands
University Medical Center Nijmegen
Nijmegen, Netherlands
Viecuri Hospital
Venlo, Netherlands
Ommelander Hospital Group
Winschoten, Netherlands
City Hospital (Sandwell and West Birmingham Hospitals NHS Trust)
Birmingham, United Kingdom
University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom
Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom
Poole Hospital NHS Foundation Trust
Poole, United Kingdom
Good Hope Hospital (Heart of England NHS Foundation Trust)
Sutton Coldfield, United Kingdom
De With RR, Rienstra M, Smit MD, Weijs B, Zwartkruis VW, Hobbelt AH, Alings M, Tijssen JGP, Brugemann J, Geelhoed B, Hillege HL, Tukkie R, Hemels ME, Tieleman RG, Ranchor AV, Van Veldhuisen DJ, Crijns HJGM, Van Gelder IC. Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation: results of the RACE 3 study. Europace. 2019 Apr 1;21(4):563-571. doi: 10.1093/europace/euy311.
Rienstra M, Hobbelt AH, Alings M, Tijssen JGP, Smit MD, Brugemann J, Geelhoed B, Tieleman RG, Hillege HL, Tukkie R, Van Veldhuisen DJ, Crijns HJGM, Van Gelder IC; RACE 3 Investigators. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial. Eur Heart J. 2018 Aug 21;39(32):2987-2996. doi: 10.1093/eurheartj/ehx739.
Primary Completion
February 1, 2018
Actual (reported)Study Completion
January 31, 2021
Actual (reported)Last Updated
August 19, 2021
Record last verified: 2021-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: